Section of Nephrology and Selzman Institute for Kidney Health, Baylor College of Medicine, Houston TX.
Section of Nephrology and Selzman Institute for Kidney Health, Baylor College of Medicine, Houston TX; Center for Innovations in Quality, Effectiveness, and Safety, Baylor College of Medicine, Houston TX; Baker Institute for Public Policy, Rice University, Houston TX.
Am J Kidney Dis. 2018 Apr;71(4):479-487. doi: 10.1053/j.ajkd.2017.09.024. Epub 2017 Dec 23.
Many patients in the United States have limited or no health insurance at the time they develop end-stage renal disease (ESRD). We examined whether health insurance limitations affected the likelihood of peritoneal dialysis (PD) use.
Retrospective cohort analysis of patients from the US Renal Data System initiating dialysis therapy in 2006 through 2012.
SETTING & PARTICIPANTS: We identified socioeconomically similar groups of patients to examine the association between health insurance and PD use. Patients aged 60 to 64 years with "limited insurance" (defined as having Medicaid or no insurance) at ESRD onset were compared with patients aged 66 to 70 years who were dually eligible for Medicare and Medicaid at ESRD onset.
Type of insurance coverage at ESRD onset.
The likelihoods of receiving PD before dialysis month 4, when all patients qualified for Medicare due to ESRD, and of switching to PD therapy following receipt of Medicare.
After adjusting for observable patient and geographic differences, patients with limited insurance had an absolute 2.4% (95% CI, 1.1%-3.7%) lower probability of PD use by dialysis month 4 compared with patients with Medicare at ESRD onset. The association between insurance and PD use reversed when patients became Medicare eligible; patients with limited insurance had a 3-fold higher rate of switching to PD therapy between months 4 and 12 of dialysis (HR, 2.9; 95% CI, 1.8-4.6) compared with patients with Medicare at ESRD onset.
Because this study was observational, there is a potential for bias from unmeasured patient-level factors.
Despite Medicare's policy of covering patients in the month that they initiate PD therapy, insurance limitations remain a barrier to PD use for many patients. Educating providers about Medicare reimbursement policy and expanding access to pre-ESRD education and training may help overcome these barriers.
许多美国患者在发展至终末期肾病(ESRD)时都存在有限或没有医疗保险。我们研究了医疗保险限制是否会影响腹膜透析(PD)的使用。
对 2006 年至 2012 年期间在美国肾脏数据系统中开始透析治疗的患者进行回顾性队列分析。
我们确定了社会经济相似的患者群体,以研究医疗保险与 PD 使用之间的关系。在 ESRD 发病时具有“有限保险”(定义为拥有医疗补助或无保险)的 60 至 64 岁患者与在 ESRD 发病时同时有资格获得医疗保险和医疗补助的 66 至 70 岁患者进行比较。
ESRD 发病时的保险类型。
在所有患者因 ESRD 而有资格获得医疗保险的透析第 4 个月前接受 PD 的可能性,以及在获得医疗保险后转为 PD 治疗的可能性。
在调整了可观察到的患者和地理差异后,与 ESRD 发病时即有医疗保险的患者相比,有限保险的患者在透析第 4 个月前接受 PD 的绝对概率低 2.4%(95%CI,1.1%-3.7%)。当患者有资格获得医疗保险时,保险与 PD 使用之间的关系发生了逆转;与 ESRD 发病时即有医疗保险的患者相比,有限保险的患者在透析的第 4 至 12 个月期间转为 PD 治疗的比率高 3 倍(HR,2.9;95%CI,1.8-4.6)。
由于本研究是观察性的,因此可能存在未测量的患者水平因素导致的偏倚。
尽管医疗保险政策涵盖在开始 PD 治疗的当月的患者,但保险限制仍然是许多患者接受 PD 的障碍。教育提供者有关医疗保险报销政策,并扩大获得 ESRD 前教育和培训的机会,可能有助于克服这些障碍。